What is the price difference between ivonib and vorasidenib?
Ivosidenib (Ivosidenib) is a targeted drug targeting isocitrate dehydrogenase-1 (IDH1). It is mainly used to treat patients with IDH1-mutated acute myeloid leukemia (AML), including adult patients with newly diagnosed, relapsed or refractory AML and locally advanced or metastatic cholangiocarcinoma. Vorasidenib (Vorasidenib) is a drug that acts on both isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2). It is mainly used to treat children and adults aged 12 years and older with grade 2 astrocytoma or oligodendroglioma who have IDH1 or IDH2 mutations after surgery (including biopsy, subtotal resection or total resection).

Currently, the original research version of ivonib has been launched in China, but it has not yet been included in medical insurance. The common specifications on the market are 0.25g 60 tablets/box, priced at about RMB 70,000. Overseas, the price of the original research version of Avonib may be as high as more than 200,000 yuan (which may fluctuate due to exchange rates). However, generic drugs of ivonib are already sold overseas, and their ingredients are basically the same as the original drug. For example, the 250mg 60-tablet version produced in Laos has a relatively low price of only more than 3,000 yuan per box (the price may change due to exchange rates).
In contrast, the original drug of vorsidenib has not yet been launched in China, so its price, medical insurance and other related information are not yet clear. However, according to overseas news, the original drug of Voxanib (specification: 40mg*30 tablets/box) may be priced as high as more than 300,000 yuan, which is expensive. However, generic drugs of vorsidenib have been launched overseas, and their drug ingredients are basically the same as the original drugs. For example, drugs with the same specifications produced by a Lao pharmaceutical factory are sold for only more than 7,000 yuan (the price may fluctuate due to exchange rates).
Reference: https://www.tibsovo.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)